The growing incidence of lymphomas and the increasing age of the population in western countries prompt clinicians to face more and more frequently the treatment of elderly aggressive lymphomas. Moreover, once an accurate geriatric assessment has been carried out and the patient is willing and able to receive a curative-intent therapy, the clinician has to choose among different therapeutic regimens. Herein we discuss the role of Rituximab-CHOP vs two-weekly CHOP + G-CSF in the aggressive lymphoma of the elderly.
File in questo prodotto:
Non ci sono file associati a questo prodotto.